May 8, 2018 / 11:28 AM / 2 months ago

BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 Mln-$185 Mln

May 8 (Reuters) - Intercept Pharmaceuticals Inc:

* INTERCEPT PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS, ISSUES 2018 OCALIVA NET SALES GUIDANCE AND PROVIDES BUSINESS UPDATE

* Q1 REVENUE $36 MILLION VERSUS I/B/E/S VIEW $38.2 MILLION

* 2018 WORLDWIDE OCALIVA NET SALES CURRENTLY EXPECTED TO BE BETWEEN $170 MILLION AND $185 MILLION

* INTERCEPT - CONFIRMING PREVIOUSLY ANNOUNCED 2018 NON-GAAP ADJUSTED. OPERATING. EXPENSES GUIDANCE RANGE OF BETWEEN $390 MILLION AND $410 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below